Axonics Stock Forecast, Price & News

-1.31 (-1.98 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume391,049 shs
Average Volume380,042 shs
Market Capitalization$2.72 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Axonics logo

About Axonics

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.52 out of 5 stars

Medical Sector

1157th out of 4,434 stocks

Surgical & Medical Instruments Industry

107th out of 366 stocks

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Axonics (NASDAQ:AXNX) Frequently Asked Questions

Is Axonics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics
or view top-rated stocks.

What stocks does MarketBeat like better than Axonics?

Wall Street analysts have given Axonics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Axonics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Axonics' next earnings date?

Axonics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Axonics

How can I listen to Axonics' earnings call?

Axonics will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Thursday, May, 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.16. The business had revenue of $32.90 million for the quarter, compared to analysts' expectations of $27.89 million. Axonics had a negative net margin of 52.60% and a negative trailing twelve-month return on equity of 19.35%. The company's revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.43) EPS.
View Axonics' earnings history

How has Axonics' stock price been impacted by COVID-19 (Coronavirus)?

Axonics' stock was trading at $30.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXNX shares have increased by 114.9% and is now trading at $64.94.
View which stocks have been most impacted by COVID-19

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $176 million-$180 million, compared to the consensus revenue estimate of $169.92 million.

What price target have analysts set for AXNX?

7 analysts have issued 1 year price objectives for Axonics' stock. Their forecasts range from $57.00 to $78.00. On average, they expect Axonics' stock price to reach $67.33 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts' price targets for Axonics
or view top-rated stocks among Wall Street analysts.

Who are Axonics' key executives?

Axonics' management team includes the following people:

What is Raymond W. Cohen's approval rating as Axonics' CEO?

12 employees have rated Axonics CEO Raymond W. Cohen on Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

Who are some of Axonics' key competitors?

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

How do I buy shares of Axonics?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $64.94.

How much money does Axonics make?

Axonics has a market capitalization of $2.72 billion and generates $111.54 million in revenue each year. The company earns $-54,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Axonics have?

Axonics employs 416 workers across the globe.

What is Axonics' official website?

The official website for Axonics is

Where are Axonics' headquarters?

Axonics is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.